849676-07-9

Basic information

• Product Name: 5″-azide-1,3,2′,6′,2′″,6′″-hexa-N-(tert-butoxycarbonyl)-5″-deoxy-neomycin B
• Synonyms: 5″-azide-1,3,2′,6′,2′″,6′″-hexa-N-(tert-butoxycarbonyl)-5″-deoxy-neomycin B
• CAS NO: 849676-07-9
• Molecular Weight: 1240.37
• Mol File: 849676-07-9.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: 5″-azide-1,3,2′,6′,2′″,6′″-hexa-N-(tert-butoxycarbonyl)-5″-deoxy-neomycin B(CAS DataBase Reference)
• NIST Chemistry Reference: 5″-azide-1,3,2′,6′,2′″,6′″-hexa-N-(tert-butoxycarbonyl)-5″-deoxy-neomycin B(849676-07-9)
• EPA Substance Registry System: 5″-azide-1,3,2′,6′,2′″,6′″-hexa-N-(tert-butoxycarbonyl)-5″-deoxy-neomycin B(849676-07-9)

Safety Data

• Hazardous Substances Data: 849676-07-9(Hazardous Substances Data)

Upstream product

• 119-04-0 neomycin B 
• 4146-30-9 neomycin B trisulfate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1374650-62-0 C₆₂H₁₁₄N₆O₂₅Si 
• 1067241-20-6 1,3,2',6',2''',6''-hexa-N-(tert-butoxycarbonyl)-5''-O-(p-methylbenzenesulfonyl)-neomycin 
• 241820-93-9 1,3,2′,6′,2?,6?-hexa-N-(tert-butoxycarbonyl)-5″-O-(2,4,6-triisopropylbenzenesulfonyl)-neomycin 

Downstream Products

• 1134204-69-5 1,3,2',6',2''',6'''-hexa-N-(tert-butoxycarbonyl)-5''-deoxy-5''-(4-(β-alanyl(Fmoc)-Gly-OBn)-[1,2,3]-triazol-1-yl)-neomycin 
• 1357190-44-3 C₆₄H₁₀₄ClN₉O₂₅ 
• 1357190-46-5 C₆₈H₁₀₂Cl₃N₉O₂₆ 
• 1357190-47-6 C₇₇H₁₂₁Cl₂N₉O₂₅ 
• 1357190-45-4 C₆₇H₁₁₀ClN₉O₂₅ 
• 1357190-48-7 C₇₁H₁₀₈Cl₃N₉O₂₆ 
• 1357190-49-8 C₈₀H₁₂₇Cl₂N₉O₂₅ 
• 1350451-67-0 C₁₁₆H₁₉₂N₁₈O₄₈ 
• 1350451-66-9 C₁₁₆H₁₉₂N₁₈O₄₈ 
• 1092548-12-3 C₂₇H₅₁N₇O₁₅ 

Relevant articles and documents

RNA-selective modification by a platinum(II) complex conjugated to amino- and guanidinoglycosides

Revving up the RNA response: Binding of the anticancer drug cisplatin (cis-Pt) to nucleic acids is believed to favor DNA over RNA. To "reverse" the nucleic acid selectivity of cis-Pt, amino- and guanidinoglycoside-PtII conjugates (1 and 2) have

Synthesis of nucleobase-neomycin conjugates and evaluation of their DNA binding, cytotoxicities, and antibacterial properties

Neomycin is known to preferentially bind to A-form nucleic acid structures including triplex DNA, DNA and RNA hybrid, and duplex RNA. Tethering a DNA intercalator moiety to the C5” position of the ring III of neomycin is a practical approach to develop po

Arginine-linked neomycin B dimers: Synthesis, rRNA binding, and resistance enzyme activity

The nucleotides comprising the ribosomal decoding center are highly conserved, as they are important for maintaining translational fidelity. The bacterial A-site has a small base variation as compared with the human analogue, allowing aminoglycoside (AG) antibiotics to selectively bind within this region of the ribosome and negatively affect microbial protein synthesis. Here, by using a fluorescence displacement screening assay, we demonstrate that neomycin B (NEO) dimers connected by l-arginine-containing linkers of varying length and composition bind with higher affinity to model A-site RNAs compared to NEO, with IC50 values ranging from ~40-70 nM, and that a certain range of linker lengths demonstrates a clear preference for the bacterial A-site RNA over the human analogue. Furthermore, AG-modifying enzymes (AMEs), such as AG O-phosphotransferases, which are responsible for conferring antibiotic resistance in many types of infectious bacteria, demonstrate markedly reduced activity against several of the l-arginine-linked NEO dimers in vitro. The antimicrobial activity of these dimers against several bacterial strains is weaker than that of the parent NEO.